Analysis of micro RNA in blood serum samples from patients with digestive tract cancer
Not Applicable
- Conditions
- Esophageal cancer, gastric cancer, gastric submucosal tumor, gastrointestinal stromal tumor, colon cancer and pancreas cancer
- Registration Number
- JPRN-UMIN000008929
- Lead Sponsor
- Digestive Disease Center, Showa University Northern Yokohama Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
(1) synchronous or metachronous malignancy (2) pregnant or breastfeeding women
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Analysis of micro RNA
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie miRNA expression changes in digestive tract cancers as studied in JPRN-UMIN000008929?
How do serum miRNA profiles from JPRN-UMIN000008929 compare to standard-of-care biomarkers for early detection of esophageal and gastric cancers?
Which specific miRNA biomarkers identified in JPRN-UMIN000008929 correlate with prognosis or treatment response in gastrointestinal stromal tumors and pancreatic cancer?
What adverse events are associated with miRNA-based diagnostics in digestive cancer patients, and how are they managed clinically?
Are there combination therapies involving miRNA modulators that show promise in treating RAS-driven digestive cancers like those studied in JPRN-UMIN000008929?